NCT01511874View on ClinicalTrials.gov

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

December 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

ELIGARD 22.5mg

a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks

Trial Locations (1)

Unknown

Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

HanAll BioPharma Co., Ltd.

INDUSTRY